Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Date:2/28/2013

net loss per share

$
(0.46)$
(0.33)$
(1.50)$
(1.19)Weighted average shares outstanding used in computing basic and diluted net loss per share115,179114,446114,820112,942 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Twelve Months Ended December 31,20122011Cash flows from operating activities:Net loss 

$
(171,855)$
(133,978)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense on liability related to sale of future royalties 

18,057-Non-cash royalty revenue related to sale of future royalties

(10,791)-Stock-based compensation 

16,19918,885Depreciation and amortization 

14,50814,951Impairment of long-lived assets

1,675-Other non-cash transactions

8451,359Changes in operating assets and liabilities:Accounts receivable

(867)20,164Inventory

(5,613)(5,390)Other assets

6,031(12,267)Accounts payable

(122)(3,384)Accrued compensation

(4,034)3,555Accrued expenses

1,4951,013Accrued clinical trial expenses

5,547(191)Deferred revenue

(9,384)(17,516)Interest payable

5,278-Other liabilities

3,275(943)Net cash used in operating activities 

(129,756)(113,742)Cash flows from investing activities:Purchases of property and equipment 

(10,583)(9,722)Restricted cash

(25,000)-Maturities of investments 

307,887383,052Sales of investments 

5,378210,089Purchases of investments 

(164,662)(695,371)Net cash provided by (used in) investing activities 

113,020(111,952)Cash flows from financing activities:Proceeds from issuance of senior secured notes, net

77,940-Repayment of convertible subordinated notes

(172,407)-Payment of capital lease obligations

(2,437)(1,978)Proceeds from sale of f
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty ... abstract sponsored by,the Company has been accepted ... Association 67th Scientific Sessions in Chicago.,The abstract, ... Comparison Study of Intranasal Insulin Spray,(Nasulin(TM)) and ...
... Among Patients with,Active Disease, MOUNTAIN VIEW, ... Inc., a clinical-stage biopharmaceutical company,focused on ... target the chemokine system,presented data today ... trial of,Traficet-EN (CCX282-B), an orally-active anti-inflammatory ...
Cached Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5
(Date:7/10/2014)... The Capital Institute for Neurosciences at Capital Health ... a clinical trial that delivers chemotherapy to brain tumors ... the procedure, done at Capital Health Medical Center – ... tiny catheter through the patient’s femoral artery in the ... the brain. Once the catheter reached the brain, chemotherapy ...
(Date:7/10/2014)... Colorado (PRWEB) July 10, 2014 ... will gather in Copenhagen this July 13-17 to ... bringing the world closer to breakthroughs in dementia ... the world’s largest conference of its kind. , ... AAIC serves as a catalyst for generating new ...
(Date:7/10/2014)... 10, 2014 In his latest blog ... drug treatment facility CEO Per Wickstrom has listed 5 ... trying to confirm an appointment, get information or sometimes ... following-up without being annoying is a skill that most ... a way to keep the dialogue moving without coming ...
(Date:7/10/2014)... (July 8, 2014) A new study from Colorado ... improvements, poor oral health remains a major problem in ... "The oral health among Native Americans is abysmal with ... of the country," said Terrence Batliner, DDS, MBA, associate ... at the School of Public Health. "The number one ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Teens who ... are more likely to develop emotional symptoms such as ... factors such as these that may exacerbate issues teens ... appropriate treatment and in making decisions about when to ... school for these athletes," study authors Lisa Koehl and ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... 26 Velos, Inc., the recognized leader and ... and Net.Orange, Inc., the respected healthcare Internet solutions ... Cancer Research Centers (Mary Crowley). The two companies ... for strong central clinical research infrastructure and implementation ...
... Sandals(R) Originals2 Footwear by BeechHUNTINGTON BEACH, Calif., Feb. ... Yoga Sandals(R) Originals line with new adjustable ... This patented foot therapy can now be customized ... foot , increasing flexibility and helping improve balance ...
... LLC ( http://www.GlenwoodSystems.com ) launches the GlaceComplete product suite which seamlessly ... an assisted medical billing process. The product has been designed ... maximizing revenue contribution for the average office based medical practice. ... ...
... Today, AmeriGlide announced the recipient of this years AmeriGlide Achiever Scholarship. ... a wheelchair. , ... Raleigh, NC (PRWEB) February 26, ... of the first semi-annual AmeriGlide Achiever Scholarship. The AmeriGlide Achiever Scholarship ...
... Honored for Comebacks from Ostomy SurgeryWASHINGTON, Feb. 25 ... improving the lives of other ostomates, was named this ... pilot Robert (Bob) Cuyler was named the first recipient ... ceremony here this evening. Founded in 1984 by ...
... ArvinMeritor (NYSE: ARM ) today announced that ... by Lin Cummins, senior vice president of Communications for ArvinMeritor, ... one of the most challenging economic times in history, I ... and individuals to help wipe out heart disease, the number ...
Cached Medicine News:Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 2Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 3Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 4Health News:Sandal Evolution(R) Takes a Healthy Step 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:AmeriGlide Announces Recipient of AmeriGlide Achiever Scholarship 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 3Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 4Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 5Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 6Health News:ArvinMeritor Proud to Sponsor American Heart Association Campaign 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: